Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A carries a market capitalization of 8.50B, placing it among publicly traded companies globally. Its enterprise value stands at 10.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A has 316.05M shares outstanding.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 32.62. The price-to-sales ratio is 4.17, and the price-to-book ratio stands at 2.75.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 27.89 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.89 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 10.39B versus a market cap of 8.50B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A maintains a current ratio of 1.14, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 91.30, indicating elevated leverage, while an interest coverage ratio of 4.96 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 8.81, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.30 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.16, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.53, useful for judging operating efficiency across full business cycles. The company generates approximately 895,016.99 in revenue per employee across its workforce of 2,277.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.09 indicates how many times Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A recorded 27.13M in income tax expense. That works out to an effective tax rate of 10.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 270.37M, leaving 260.36M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A's stock has declined approximately 26.88% over the past 52 weeks. The 50-day moving average sits at 28.27, while the 200-day moving average is 30.68.

Over the twelve months ended June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A generated 2.04B in revenue and converted that into 260.36M in net income, yielding earnings per share of 0.67. EBITDA reached 372.46M, while operating income came in at 595.01M.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A holds 956.79M in cash and equivalents against 2.83B in total debt, resulting in a net debt position of 1.35B. Total book value stands at 3.09B, with working capital of 317.16M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A posted a gross margin of 57.99, reflecting its pricing power and cost economics. The operating margin of 29.20 and net profit margin of 12.78 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A paid dividends of 1.14 per share. The dividend payout ratio of 159.27 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -3.85, meaning Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A's most recent stock split took place on June 12, 2025 with a 5:7 split ratio.

As of June 30, 2026, Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 2.17, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.